Novo Nordisk lifts guidance after forecast-beating 3Q profit of $1.91 billion


By Dominic Chopping

Danish pharmaceutical company Novo Nordisk AS on Wednesday raised full-year guidance and reported a third-quarter net profit that beat expectations amid strong demand for its diabetes care and obesity treatments.

Net profit rose to 14.41 billion Danish kroner ($1.91 billion) from DKK12.12 billion in the same period last year, beating the DKK13.95 billion forecast by analysts in a FactSet poll.

Sales rose 28% to DKK45.57 billion, against analysts’ expectations of DKK44.5 billion.

Global sales were driven by diabetes and obesity care sales as GLP-1 sales increased by 44% in local currencies, obesity care sales increased by 62% and rare disease sales increased by 4%, partially offset by a 15% decrease in insulin sales, the company said.

Full-year guidance was raised, with the company now expecting 2022 sales growth of 14%-17% from 12%-16% previously, and operating-profit growth of 13%-16% from 11%-15%, both measured in local currencies.

Reported growth in sales is now seen around 10 percentage points higher than in local currencies from 9 percentage points higher previously, while reported operating-profit growth is seen around 15 percentage points higher from around 14 percentage points higher previously.

Write to Dominic Chopping at

This article was originally published by Read the original article here.

Previous articleTesla shuts main showroom in Beijing in shift of China strategy: report
Next articleDow Jones Newswires: Aston Martin Lagonda global Q3 loss doubled; lowers 2022 guidance


Please enter your comment!
Please enter your name here